Bluejay Diagnostics (BJDX) said it closed Friday an underwritten public offering of under 5.4 million common or prefunded units, with expected gross proceeds of roughly $8.8 million.
Net proceeds will be used to repay $2.3 million in debt, finance clinical studies and other activities related to seeking US Food and Drugs Administration approval, and for general working capital, the company said.
Bluejay Diagnostics' shares fell 6.8% in recent trading Friday.
Price: 0.70, Change: -0.05, Percent Change: -6.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments